Induction of cytokines and growth factors by rapamycin in the microenvironment of brain metastases of lung cancer by 源��꽭�썕
ONCOLOGY LETTERS  5:  953-958,  2013
Abstract. The association between rapamycin and astrocytes 
in a tumor-bearing mouse model with brain metastases of 
non-small cell lung cancer (NSCLC) was investigated. For 
in vitro experiments, NCI-H358, a human lung adenocarci-
noma cell line, was co-cultured with immortalized astrocytes, 
and treated with rapamycin, an mTOR inhibitor. We evalu-
ated the expression of interleukin-1 (IL-1), interleukin-3 
(IL-3), interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), 
transforming growth factor-β (TGF-β), insulin-like growth 
factor-1 (IGF-1), platelet-derived growth factor (PDGF), 
chemoattractant protein-1 (MCP-1) and macrophage inflam-
matory protein-1 (MIP-1) in tumor cells in vivo. Rapamycin is 
cytotoxic in vitro; however, co-culturing tumor cells and astro-
cytes induced tumor cell survival. IL-1, IL-3, IL-6, TNF-α, 
TGF-β, PDGF, MCP-1 and MIP-1 expression were higher 
in rapamycin-treated mice compared to the control group, 
however, IGF-1 expression was lower. Notably, treatment with 
rapamycin before inoculating tumor cells affected cytokine 
expression in the tumor microenvironment. We suggest that 
growth factors and cytokines in the tumor microenvironment 
play a role in the survival of cancer cells in brain metastases. 
Introduction
Lung cancer is the leading cause of cancer-related mortality in 
the United States and Europe, and 80% of cases are diagnosed 
as non-small cell lung cancer (NSCLC). Although NSCLC 
frequently develops brain metastasis, effective treatment and 
prevention for brain metastasis remain unavailable (1,2).
Metastases form when specialized tumor cells (‘seeds’) find 
a suitable environment (‘soil’) to arrest, invade and grow (3). 
Metastasis patterns to different organs are dependent on the 
tumor cell phenotype and interactions between the tumor cell 
and the environment, such as cellular components, cytokines 
and organ-derived growth factors (4). 
In the central nervous system, glial cells, which have 
traditionally been viewed as providing structural support 
for neurons, also play an important role in maintaining 
homeostasis. Astrocytes support immune defense in the 
brain and protect neuronal cells from waste products and 
hypoxic damage. Astrocytes also produce a wide variety 
of cytokines, including interleukin-1 (IL-1), interleukin-3 
(IL-3), interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), 
transforming growth factor-β (TGF-β), insulin-like growth 
factor-1 (IGF-1) and platelet-derived growth factor (PDGF). 
Cytokines released by activated microglia include IL-1, IL-6, 
TNF-α, monocyte chemoattractant protein-1 (MCP-1) and 
macrophage inflammatory protein-1 (MIP-1). MCP-1 recruits 
NK cells and a subpopulation of T-lymphocytes. MIP-1 
attracts activated/memory T-cells, monocytes/macrophages, 
and immature dendritic cells (5-7). 
It has recently been postulated that maintaining E-cadherin 
expression could potentially block increases in motility and 
invasion during epithelial-to-mesenchymal transitions (EMT). 
It has further been suggested that the brain microenvironment 
could be affected by pre-treatment with peroxisome 
proliferator-activated receptor γ (PPARγ)-activating drugs, 
even before brain metastasis (8). 
Rapamycin, a lipophilic macrolide antibiotic, was 
originally identified as a fungicide and immunosuppressant. 
Studies have revealed, however, that rapamycin can potently 
arrest the growth of cells derived from a broad spectrum of 
cancers. Rapamycin has been shown to specifically inhibit 
mammalian target of rapamycin (mTOR), which is a key player 
in tumor development and progression (9). Rapamycin can 
impede tumor metastasis by suppressing tumor angiogenesis 
and lymphangiogenesis (10,11).
A dynamic interaction likely exists between cancer cells 
and the host microenvironment to support cancerous growth 
and spread. The aim of this study was to identify interactions 
between astrocytes and rapamycin in brain metastases of 
NSCLC.
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Materials and methods
Apoptosis assay. NCI-H358, a human lung adenocarci-
noma cell line, was obtained from the American Tissue 
Culture Collection (Manassas, VA, USA). NCI-H358 
tumor cells (1x104 cells/well) were plated in 96-well flat 
bottomed tissue culture plates and incubated at 37˚C in a 
5% CO2/95% air atmosphere. Rapamycin (10 or 100 µg/ml) 
was then added to tumor cells cultured alone or co-cultured 
with astrocytes. Following 24, 48 or 72 h  rapamycin 
treatment, 10 µl MTT (3-(4,5-Dimethylthiazol-2-yl)-
2,5-diphenyltetrazoliumbromide) stock solution (EZ Cytox, 
Daeil Lab Service Co., Seoul, Korea) was added to each well, 
and the plates were incubated for 4 h. Plates were agitated on 
a plate shaker for 3 sec, and the absorbance at 540 nm was 
determined using a scanning multi-well spectrophotometer 
(VERSA max, Sunnyvale, CA, USA).
Co-culture of astrocytes and NCI-H358, and rapamycin 
administration. Immortalized astrocytes were plated on 
sterile 0.4 μm cell culture inserts (Becton-Dickinson Labware, 
Franklin Lakes, NJ, USA) at a density of 4x105 cells in 1 ml 
Dulbecco's modified Eagle's medium (DMEM) containing 
10% fetal bovine serum (FBS). The inserts were gently trans-
ferred to empty 6-well plates and placed in at 37˚C. NCI-H358 
lung adenocarcinoma cells were plated in 6-well plates at a 
density of 5x105 cells/well in 2 ml of RPMI-1640 containing 
10% FBS. After incubating overnight, the medium of both 
cultures was removed and replaced with serum-free medium. 
Inserts containing astrocytes were transferred to 6-well 
plates containing tumor cells and co-cultured for 24, 48 and 
72 h. Control samples consisted of cell-free inserts placed in 
6-well plates containing tumor cells. At each time point the 
inserts were discarded and the tumor cells were washed with 
ice-cold PBS and lysed with buffer. NCI-H358 cells alone 
and co-cultured with astrocytes were treated with rapamycin 
(100 g/ml) 24 h later. 
This study was approved by the Ethics Committee of 
St. Vincent's Hospital, The Catholic University of Korea, 
Suwon, Korea. 
Inoculation of intracranial cancer cells and experimental 
design. The nude mice were anesthetized with an 
intraperitoneal (i.p.) injection of 12 mg/kg xylazine (Rompun; 
Cutter Laboratories, Shawnee, KS, USA) and 30 mg/kg 
ketamine (Ketalar; Parke-Davis & Co., Morris Plains, NJ, 
USA). The mice were then stereotaxically inoculated with 
1x106 NCI-H358 cells into the right frontal lobe (2 mm lateral 
and 1 mm anterior to the bregma, at a depth of 2.5 mm from the 
skull) using a sterile Hamilton syringe fitted with a 26-gauge 
needle (Hamilton Co., Reno, NV, USA) and a microinfusion 
pump (Harvard Apparatus, Holliston, MA, USA). Intracranial 
tumors were confirmed by cranial magnetic resonance 
imaging (MRI). All MRI experiments were performed on a 
4.7 T animal MRI scanner (BioSpec 47/40, Bruker, Germany) 
with a quadrature volume coil (diameter, 25 mm) at the Korea 
Basic Science Institute in Ochang, Korea.
The experimental design is shown in Fig. 1. Both 
experimental groups contained five mice initially. In the first 
group, mice were treated with rapamycin (1.5 mg/kg) via 
i.p. injection 3 times a week for 4 weeks before intracranial 
inoculation with NCI-H358 cells. In the second treatment group, 
mice were treated with rapamycin (1.5 mg/kg) via i.p. injection 
3 times a week for 4 weeks after intracranial inoculation. 
Control and treated mice were euthanized 12 weeks after the 
intracranial inoculation, and tumor specimens were obtained 
for RT-PCR.
Reverse transcription-polymerase chain reaction (RT-PCR). 
Total RNA from all specimens was extracted using a 
commercial kit (RNeasy Mini kit, Qiagen, Hilden, Germany). 
One microgram of total RNA was reverse transcribed using 
the RT-premix (M-Biotech, Seoul, Korea). RT-PCR was 
performed on cDNA samples using a DNA Thermal Cycler 
(Bio-Rad, Hercules, CA, USA) with Go Taq Green Master mix 
(Promega, Madison, WI, USA), RNase-free water and primers. 
The primer sequences are summarized in Table I. RT-PCR 
products were separated on a 1.5% agarose gel containing 
ethidium bromide and visualized with UV light.
Statistical analysis. All data are shown as the means ± SEM. 
Comparisons between groups were made using unpaired 
Student's t-tests, and among multiple groups by ANOVA.  P<0.05 
was considered to indicate a statistically significant result.
Results
Astrocytes and rapamycin induce apoptosis of NCI-H358 
cells. Rapamycin inhibits survival of NCI-H358 lung cancer 
cells in a dose- and time-dependent manner. To determine 
whether astrocytes affect tumor cell survival, astrocytes were 
co-cultured with NCI-H358 lung cancer cells. Co-culture 
with astrocytes induced NCI-H358 cell survival, compared 
with NCI-H358 cells alone. Moreover, rapamycin (100 µg/ml) 
enhanced the survival of lung cancer cells in co-culture (Fig. 2).
Modulation of cytokines and growth factors by rapamycin 
in brain metastasis model. Activated astrocytes produce a 
wide variety of cytokines, including IL-1, IL-3, IL-6, TNF-α, 
TGF-β, IGF-1 and PDGF. Cytokines released by activated 
microglia include IL-1, IL-6, TNF-α, MCP-1, and MIP-1. 
IL-1, IL-3, IL-6, TNF-α, TGF-β, PDGF, MCP-1 and MIP-1 
Figure 1. Therapeutic schedule. 
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expression was higher in rapamycin-treated mice compared 
with controls (Fig. 3). IGF-1 expression, however, was lower 
in rapamycin-treated mice than control mice. Rapamycin 
treatment before tumor cell inoculation affected the later 
cytokine expression in the tumor. The tumor progressively 
increased in size, and compressed the brain parenchyma at 
4, 8 and 12 weeks after inoculation in control mice. In mice 
treated with rapamycin before inoculation, the tumor formed 
and thrived slowly (Fig. 4).
Discussion
Rapamycin caused apoptosis of tumor cells alone. However, 
co-cultures of astrocytes with NCI-H358 lung cancer cells 
prevented apoptosis of tumor cells even after rapamycin 
treatment. In the experimental mouse model, IL-1, IL-3, IL-6, 
TNF-α, TGF-β, PDGF, MCP-1 and MIP-1 expression in the 
inoculated tumors increased in rapmycin-treated mice. IGF-1 
expression, however, decreased. 
Co-culturing breast or lung cancer cells with astrocytes 
led to upregulated survival genes, including GSTA5, 
BCL2L1 and TWIST1, in tumor cells (12). Brain metastases 
are surrounded and infiltrated by activated astrocytes and are 
highly resistant to chemotherapy. Astrocytes in co-culture 
were activated by tumor cell-oriented factors, including 
macrophage migration inhibitory factor (MIF), IL-8 and 
plasminogen activator inhibitor-1 (PAI-1). Interactions 
between metastatic tumor cells and activated astrocytes are 
Table I. Primer pairs for reverse transcription-polymerase chain reaction (RT-PCR).
mRNA Direction Sequence Length (bp)
IL-1 Forward GAGAGCCGGGTGACAGTATC 
 Reverse ACTTCTGCCTGACGAGCTTC 202
IL-3 Forward TGCCTACATCTGCGAATGAC 
 Reverse TTAGGTGCTCTGCCTGCTG 203
IL-6 Forward ACTTCCATCCAGTTGCCTTC  
 Reverse CAGAATTGCCATTGCACAAC 201
TNF-α Forward CCCATGGATGTCCCATTTAG 
 Reverse CCAGGATTCTGTGGCAATC 193
ATGF-β Forward GTGGTTTCTGTGACCCTTGG 
 Reverse CCAGTCACACAGGCAACAAG 201
IGF-1 Forward CTCTTCTACCTGGCGCTCTG 
 Reverse GCAACACTCATCCACAATGC 195
PDGF-A Forward CCCCTGCCCATTCGGAGGAAGAG 
 Reverse TTGGCCACCTTGACGCTGCGGTG 203
MCP-1 Forward CTCACCTGCTGCTACTCATTC 
 Reverse GCTTGAGGTGGTTGTGGAAAA 650
MIP-1 Forward TCAGCACCATGAAGGTCTCCAC 
 Reverse CTCAGGCATTTAGTTCCAGCTC  450
Figure 2. (A) The effect of rapamycin on NCI-H358 cell growth. NCI-H358 cells were treated with 10 or 100 µg/ml rapamycin for 24, 48 or 72 h. Cell growth 
was determined by methyl thiazolyl tetrazolium assay (MTT). Rapamycin inhibited survival of NCI-H358 lung cancer cells in a dose- and time-dependent 
manner. 0 µg/ml of rapamycin represents the control group. (B) Co-culturing NCI-H358 cells and immortalized astrocytes induced tumor cell survival, even 
with rapamycin treatment. Data are presented as mean ± SEM (n=6 wells per measurement). *P<0.05 vs. tumor cells only. 
  A   B
KIM et al:  RAPAMYCIN MODULATES MICROENVRIONMENT IN BRAIN METASTASES956
important in creating a favorable microenvironment for the 
tumor cells in the brain (13). 
The expression of cytokines and growth factors in the 
tumor-bearing mouse model was measured to investigate the 
role of rapamycin in the microenvironment of brain metastases. 
IL-1 is a macrophage-derived proinflammtory ‘alarm’ 
cytokine that mediates inflammation. Balanced IL-1 levels 
have been associated with inducing antitumor immunity (14). 
IL-3 gene expression within tumors leads to host-cell 
infiltration, particularly by macrophages, slower tumor 
growth and enhanced immunogenicity (15). IL-6 has been 
shown to inhibit growth and enhance motility in breast 
cancer cell lines (16). TNF-α has an antitumor effect in 
murine tumors and human tumor xenografts in vivo and 
appears to be cytotoxic to many human tumor cell lines 
in vitro (17). TGF-β is an important suppressor of primary 
tumorigenesis. The role of TGF-β in apoptosis and cell cycle 
arrest depends on the microenvironment (18). PDGF induces 
important cellular processes including chemotaxis, survival, 
apoptosis and transformation in vitro (19). MCP-1, also 
known as chemokine ligand 2 (CCL2), is a pro-inflammatory 
chemokine that recruits and activates monocytes during 
Figure 4. Serial magnetic resonance imaging (MRI). (A) A tumor was noted in the cortex of the right hemisphere 4 weeks after intracranial inoculation 
of 1x106 NCI-H358 cells (left). The tumor size progressively increased and compressed the brain parenchyma at 8 weeks (middle) and 12 weeks (right) 
after the inoculation of control mice. (B) In mice treated with rapamycin before inoculation, the tumor formed and thrived relatively slowly. Left, 4 weeks; 
middle, 8 weeks; right, 12 weeks.
Figure 3. Reverse transcription-polymerase chain reaction (RT-PCR) results. Interleukin-1 (IL-1), IL-3, IL-6, tumor necrosis factor-α (TNF-α), transforming 
growth factor-β (TGF-β), platelet-derived growth factor (PDGF), chemoattractant protein-1 (MCP-1) and macrophage inflammatory protein-1 (MIP-1) expres-
sion increased following rapamycin administration. Expression was higher in mice treated with rapamycin before inoculation than control mice. Conversely, 
IGF-1 expression decreased. Data are presented as mean ± SEM (n=4 each). *P<0.05 vs. control.
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the inflammatory response. MCP-1 is a pivotal regulator of 
tumor growth, progression and metastasis (20,21). MCP-1 
and MIP-1 have been reported to regulate immunity to 
melanoma by promoting lymphocyte infiltration into tumors 
and subsequent cytokine production (22,23). MCP-1 or MIP-1 
loss significantly promotes primary tumor growth and lung 
metastasis by inhibiting IL-6, TNF-α and TGF-β expression. 
In this study, IGF-1 levels decreased in rapamycin-treated 
mice. IGF-1 is critical to activate and sustain an inflammatory 
response in the liver, which is needed for hepatic metastasis, 
not only through direct, paracrine effects on tumor cell 
growth, but also through indirect effects involving the 
tumor microenvironment (24). IGF-1 receptor expression 
in neuroblastoma cells has been reported to increase tumor 
cell interaction with the bone microenvironment, resulting in 
greater metastasis formation (25). 
Rapamycin is highly lipophilic and thus penetrates the 
blood brain barrier (BBB) (26). Combined treatment with 
rapamycin and brain penetrant MEK inhibitor significantly 
reduces brain metastasis by prohibiting perivascular invasion 
of tumor cells and tumor angiogenesis in triple-negative breast 
cancer models (27). Rapamycin effectively inhibits cancer 
metastasis in various preclinical models (28-31). 
The results demonstrated that several cytokines and growth 
factors, except for IGF-1, were increased in mice treated with 
rapamycin before inoculation, compared with control mice. 
Brain MRIs of tumor-bearing mice showed that tumor growth 
was slower in pre-treated mice than in control mice. These 
results suggest that rapamycin administration influences the 
brain microenvironment before brain metastases develop. 
Accumulating evidence indicates that metastatic progression 
is regulated, in large part, by interactions between tumor cells 
and non-tumor cells in the brain microenvironment (32,33). 
Astrocytes could contribute to the microenvironment 
associated with metastatic cell growth, and they are a source of 
cytokines and growth factors, which may modulate metastatic-
cell growth. The results suggest that modulating the brain 
microenvironment could be worthy of further research as a 
new target to prevent brain metastasis of NSCLC.
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